Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026

April 2019 | 1200 pages | ID: G66100CFD5EEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026' Report Highlights:

• Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026
• Cell Therapy Clinical Trial Insight by Indication, Company & Country
• Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
• Globally Marketed Cell Therapies: 25 Cell Therapies
• Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
• Price & Product Insight By Region/Country
• Regional Analysis of the Cell Therapy Market

In recent years, there has been a steady increase in the interest shown in the cell therapy segment from big pharmaceutical, biotech and medical device companies. Earlier, the idea for altering a cell or a gene to cure or treat a disease was considered impossible. But with the ongoing advancements, it has now become possible in the treatment or cure of a disease with the help of cell therapy.

Cell therapies are still in the early stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that consideration will be given on how these therapies will be carried out and subsequently be delivered to the patients on a clinically relevancy scale.

Currently, there are more than 750 cell based therapies in clinical pipeline. Most of the cell therapies are in Preclinical phase followed by Phase-I clinical trials. Analysis of the pipeline shows that majority of the cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer. More than 20 cell therapies are commercially available in the market. However, when it comes to marketed products, more than half of the products that are currently available are in the tissue and skin treatment segment such as Apligraf and Dermigraf.

Few cell therapy products such as Kymriah, Provenge and Yescarta have emerged as the most promising therapeutics of the decade with excellent result in treatment of various clinical indications, but the market remains widely untapped due to the high price tag.

The cell therapy technique finds wide usage in almost all types of therapeutic areas. However, majority of the cell therapy research is currently being done in the cancer, Neurological, Cardiovascular and Inflammatory segments due to their high mortality rate among the global population. Few cell therapy research is being done in the diabetic segment too where the aim is to develop an artificial pancreas using cell therapy which would work just like a natural pancreas.

Cell therapies will also have the potential to replace many risky, costly and invasive surgeries. For many disease conditions, such as diabetes, patients are required to take a prescription on a daily basis. A cell therapy approach will substantially reduce the healthcare costs of this disease by providing a one-time treatment. In the same way cell therapy approaches to pain management will also reduce the costs of opioid-based pain medications. Cell therapy, in combination with the recent advances in iPS cell generation and CRISPR-Cas 9, also has a great opportunity in the future.

The path towards the success for cell therapy will consist of a combination of scenarios that is being imagined for the cure of diseases and is hoped that these will definitely come true in the near future. The advantages and risks of current cell therapy practices will improve translational success and accelerate clinical development of safe and efficient cell products in the future.

Contents

1. OVERVIEW OF CELL THERAPY

1.1 Introduction to Cell Therapy
1.2 History & Evolution of Cell Therapy

2. TYPES OF CELL THERAPY

2.1 Allogeneic Cell Therapy
2.2 Autologous Cell Therapy
2.3 Human Embryonic Stem Cell Therapy
2.4 Neural Stem Cell Therapy
2.5 Mesenchymal Stem Cell Therapy
2.6 Hematopoietic Stem Cell Transplantation

3. MECHANISM OF THERAPEUTIC ACTION IN CELL THERAPY

4. MANUFACTURING OF CELL THERAPIES

4.1 Models for Manufacturing Cell Therapies
4.2 Facilities for Good Manufacturing Practice

5. ADVANTAGES OF CELL THERAPY OVER CONVENTIONAL THERAPY

5.1 Anti-Aging with Cell Therapy
5.2 Addressing Other Diseases with Cell Therapy

6. PERSONALIZED CELL THERAPY

6.1 Overview of Personalized Cell Therapy
6.2 Personalized Cell Therapy Using Epigenetic Tools
6.3 Personalized Cell Therapy through Mesenchymal Stem Cells
6.4 Treatment of Parkinson’s Disease through IPSCs
6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. CELL THERAPY APPLICATION BY THERAPEUTIC AREAS

7.1 Cardiovascular Disease
7.2 Neurological Disorders
7.3 Inflammatory Diseases
7.4 Diabetes
7.5 Cancer

8. GLOBAL CELL THERAPY MARKET OUTLOOK

8.1 Current Market Scenario
8.2 Cell Therapy Market by Cell Source
  8.2.1 Induced Pluripotent Stem Cell (IPSCs)
  8.2.2 Bone Marrow
  8.2.3 Umbilical Cord Blood Derived Cells
8.3 Global Cell Therapy Clinical Pipeline (Company,Indication, Region) Overview

9. US - CELL THERAPY DOSAGE & COST ANALYSIS

9.1 Allocord
9.2 Laviv
9.3 Maci
9.4 Clevecord
9.5 Hemacord
9.6 Ducord
9.7 Provenge
9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
9.10 HPC, Cord Blood (Bloodworks)
9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
9.12 Gintuit
9.13 Kymriah*
9.14 Yescarta*
9.15 Carticel

10. SOUTH KOREA - CELL THERAPY DOSAGE & COST ANALYSIS

10.1 Cartistem
10.2 Chondron
10.3 KeraHeal
10.4 Cellgram
10.5 Cure Skin Injection

11. AUSTRALIA, EUROPE & JAPAN - CELL THERAPY DOSAGE & COST ANALYSIS

11.1 Holoclar (Europe)
11.2 Yescarta (EU)
11.3 Kymriah (EU)
11.4 Temcell HS (Japan)
11.5 Chondrocytes-T-Ortho-ACI (Australia)

12. CELL THERAPY MARKET TRENDS: GEOGRAPHICALLY

12.1 US
12.2 South Korea
12.3 Europe
12.4 Japan
12.5 China
12.6 Rest of the World
  12.6.1 Africa
  12.6.2 Middle East
  12.6.3 South America

13. ADVANCEMENTS IN CELL THERAPY

13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
13.2 Advances in Cytomegalovirus Infection Prevention & Treatment
13.3 Stem Cell Therapy for the Treatment of Parkinson’s Disease
13.4 Stem Cell Therapy for the Treatment of Alzheimer’s Disease
13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy
13.6 Role of Stem Cell Therapy in Treating Infertility
13.7 Stem Cells for Eye Diseases
13.8 Cell Therapy for Stroke and Angina Pectoris
13.9 Stem Cell Therapy in Improving Wrinkles & Acne Scars

14. TREG CELLS – THE NEXT EDGE OF CELL THERAPY

14.1 Introduction to Treg Cell
14.2 Isolation & Expansion of Treg Cell
14.3 Mechanism of Action
14.4 Clinical Trials of Treg Cell Therapy
  14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD
  14.4.2 Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg cells to Prevent Solid Organ Transplant Rejection
14.5 Treg Cell Therapy for the Treatmet of Autoinflammatory & Autoimmune Diseases
  14.5.1 Inflammatory Bowel Disease
  14.5.2 Systemic Lupus Erythematosus
  14.5.3 Autoimmune Hepatitis
  14.5.4 Pemphigus Vulgaris
  14.5.5 Allergy and Asthma
14.6 Future Prospects of Treg Cell Therapy

15. GLOBAL CELL THERAPY MARKET DYNAMICS

15.1 Market Drivers
15.2 Commercial Challenges

16. GLOBAL CELL THERAPY MARKET FUTURE PROSPECTS

17. MARKETED CELL THERAPIES CLINICAL INSIGHT BY COMPANY & INDICATION

17.1 Tisagenlecleucel (Kymriah)
17.2 Axicabtagene Ciloleucel (Yescarta)
17.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
17.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
17.5 Tonogenchoncel-L (INVOSSA-K inj)
17.6 Mesenchymal Stem Cell Therapies (Stempeucel)
17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)
17.8 Sipuleucel-T (Provenge)
17.9 Autologous Mesenchymal Stem Cell Therapy - Pharmicell
17.10 Autologous Cultured Chondrocytes (MACI)
17.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
17.13 Nalotimagene Carmaleucel (Zalmoxis)
17.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
17.15 Autologous Chondrocyte Implant - TETEC
17.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
17.17 Human Skin Replacement (CellSpray)
17.18 Leukocyte Cell Therapy (CureXcell)
17.19 Autologous Cultured Chondrocyte Implant (Carticel)
17.20 Azficel-T (Laviv)
17.21 Autologous Cultured Chondrocytes (CHONDRON)
17.22 Autologous Chondrocytes (BioCart)
17.23 Amniotic Cell Therapy (NuCel)
17.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
17.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

18. GLOBAL CELL THERAPY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

18.1 Research
18.2 Preclinical
18.3 Clinical
18.4 Phase-0
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered

19. COMPETITIVE LANDSCAPE

19.1 Athersys Inc.
19.2 Baxter Healthcare Corporation
19.3 Bone Therapeutics
19.4 Celgene Corporation
19.5 Cell Medica
19.6 Cellerant Therapeutics
19.7 FibrocellScinence
19.8 Genzyme Corporation
19.9 Green Cross Cell
19.10 Histogenics Corporation
19.11 Intrexon Corporation
19.12 Intercytex
19.13 ISTO Biologics
19.14 Macrocure
19.15 Mesoblast
19.16 Molmed
19.17 Nuo Therapeutics Inc
19.18 OmniCyte
19.19 Opexa Therapeutics
19.20 Organogenesis
19.21 Pharmicell
19.22 TCA Cellular Therapy
19.23 Stem Cell Inc.
19.24 Teva Pharmaceuticals
19.25 Tigenix
19.26 Vericel Corporation

List Of Figures

LIST OF FIGURES

Figure 1-1: Cell Therapy Pathway
Figure 1-2: Evolution of Cell Therapy
Figure 2-1: Types of Cell Therapy
Figure 2-2: Steps in Allogeneic Cell Therapy
Figure 2-3: Steps in Autologous Cell Therapy
Figure 2-4: Steps in the Derivation of Human Embryonic Stem Cells
Figure 2-5: Cardinal Neural Stem Cell Properties
Figure 2-6: Mesenchymal Stem Cells Therapy Process
Figure 3-1: Cell Therapy Mechanism
Figure 4-1: Centralized Manufacturing Model
Figure 4-2: Near Patient Manufacturing Model
Figure 5-1: Major Steps in Cell Therapy
Figure 5-2: Global- Expected Aging Population of 60+ (Billion), 2015 & 2050
Figure 5-3: Advantages of Cell Therapy as a Rejuvenation Therapy
Figure 6-1: Advantages of Personalized Cell Therapy
Figure 6-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD) Treatment
Figure 6-3: Steps of iPSC Transplantation
Figure 7-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
Figure 7-2: Cell Therapy for Cardiovascular Disease
Figure 7-3: Overview of Stem Cell Therapy in Cardiovascular Disease
Figure 7-4: Cell Therapy in Neurological Disorders
Figure 7-5: Cell Therapy in Treatment of Alzheimer's disease
Figure 7-6: Cell Therapy in Diabetes
Figure 8-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
Figure 8-2: Global - Cell Therapy Market (US$ Billion), 2018 - 2026
Figure 8-3: Process for Conventional Drug Delivery
Figure 8-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
Figure 8-5: Global- Induced Pluripotent Stem Cell Therapy Market (US$ Million), 2018 - 2026
Figure 8-6: Steps involved in Bone Marrow Transplant
Figure 8-7: Global - Cell Therapies Clinical Pipeline by Phase (%), 2019 till 2026
Figure 8-8: Global - Cell Therapies Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 8-9: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
Figure 8-10: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
Figure 8-11: Global - Cell Therapies Clinical Pipeline by Company (Number), 2019
Figure 8-12: Global - Cell Therapies Clinical Pipeline by Indication (Number), 2019
Figure 9-1: US – Allocord Infusion per Hour (Millilitres), Adult & Children
Figure 9-2: US – Laviv Average Injection Cost of Initial & Whole Session (US$), March’2019
Figure 9-3: US – Maci Cost Comparision over Mosaicplasty & Microfracture (US$)
Figure 9-4: US – Clevecord Dosage of Nucleated Cells per Killogram (Million) & Average Cost (US$)
Figure 9-5: US – Provenge Cost of Single Infusion vs Overall Cost (US$), July 2017
Figure 9-6: US – Kymriah Average Dosage of CAR positive viable T cells (Paediatric & Adults), August 2017
Figure 9-7: US – Kymriah Treatment Cost for Leukemia & Lymphomas (US$), July 2018
Figure 9-8: US – Yescarta Target Dose vs Maximum Dose of CAR-positive viable T cells, October 2017
Figure 9-9: US - Yescarta & Kymriah Overall Treatment Cost (US$), April 2018
Figure 9-10: US - Yescarta & Kymriah Estimated Payment Rate by Centers for Medicare and Medicaid Services (US$), April, 2018
Figure 9-11: US – Carticel Minimum & Maximum Cost (US$), October 2017
Figure 10-1: South Korea – Cartistem Dosage (Microlitres per cm2) & Cost (US$), October 2017
Figure 10-2: South Korea – Chondron Dosage (Millilitres per Vial) & Cost (US$), March 2019
Figure 10-3: South Korea - KeraHeal vs KeraHeal-Allo Dosage form (Miililitres Cell Suspension)
Figure 10-4: South Korea – Cellgram Dosage (Cells per 10 Millilitre) & Cost (US$), October 2017
Figure 11-1: Europe – Holoclar Minimum & Maximum Dosage (Cells per cm2) & Cost (US$), August’ 2017
Figure 11-2: European Union – Yescarta Dosage of CAR-positive viable T cells by Body Weight
Figure 11-3: European Union - Yescarta & Kymriah Treatment Cost for acute lymphoblastic leukaemia and diffuse large B-cell lymphoma (US$), August’ 2018
Figure 11-4: Japan - Temcell Dosage of Cells per Killogram Body Weight (Million)
Figure 11-5: Japan – Temcell Total Cost vs Cost per Bag (US$), October’ 2017
Figure 11-6: Australia - Ortho-ACI Constituents of Dulbecco’s Modified Eagle Medium (DMEM) nutrient mixture
Figure 11-7: Australia - Ortho-ACI Average Dose (Million Cells) & Cost of Treatment (US$)
Figure 12-1: Significance of Cell Therapy Market Technology
Figure 12-2: Drivers for Growth of Cell Therapy in Japan
Figure 12-3: Criteria Impacting Successful Cell Therapy
Figure 12-4: China Cell Therapy Market Strategy
Figure 12-5: Rest of the World – Cell Therapy Clinical Trial by Region (%), 2019
Figure 13-1: Signaling Pathway in Chronic Lymphocytic Leukemia
Figure 13-2: Advantages of Treating Rheumatoid arthritis with Umbilical Cord Mesenchymal Stem Cells
Figure 13-3: Stem Cell Therapy for the Treatment of Male Infertility
Figure 13-4: Cell Therapy for Ptients with Angina
Figure 13-5: Benefits of Stem Cell Therapy in Aesthetic Purposes
Figure 14-1: Working of CD4+ & CD25+ Regulatory T-Cell
Figure 14-2: Mechanism of Action of Treg Cell
Figure 14-3: Therapeutic Action of Treg Cell
Figure 14-4: Future Applications of Treg Cells
Figure 15-1: Global – Key Factors Driving the Cell Therapy Market
Figure 15-2: Global - Cell Therapy Market Challenges
Figure 16-1: Growth Opportunities for Cell Therapy
Figure 19-1: Bone Therapeutics Clinical Pipeline
Figure 19-2: Celgene Clinical Pipeline
Figure 19-3: Cell Medica Therapeutics Clinical Pipeline
Figure 19-4: Cellerant Therapeutics Clinical Pipeline
Figure 19-5: Fibrocell Science Clinical Pipeline
Figure 19-6: Intrexon Clinical Pipeline
Figure 19-7: Mesoblast Clinical Pipeline
Figure 19-8: Molmed Clinical Pipeline
Figure 19-9: Tigenix Clinical Pipeline
Figure 19-10: Vericel Corporation Clinical Pipeline

List Of Tables

LIST OF TABLES

Table 2-1: Difference between Allogeneic & Autologous Cell Therapy
Table 5-1: Difference between Cell Therapy & Conventional Therapy
Table 13-1: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
Table 13-2: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
Table 13-3: Results of Phase I-II Trials of Adoptive Cell Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant
Table 14-1: Functions of Effector T-Cell & Treg Cell

COMPANIES MENTIONED

Athersys Inc., Baxter Healthcare Corporation, Bone Therapeutics, Celgene Corporation, Cell Medica, Cellerant Therapeutics, FibrocellScinence, Genzyme Corporation, Green Cross Cell, Green Cross Cell, Intrexon ,Corporation, Intercytex, ISTO Biologics, ISTO Biologics, ISTO Biologics, Molmed, Nuo Therapeutics Inc, OmniCyte, Opexa Therapeutics, Organogenesis, Pharmicell, TCA Cellular Therapy, TCA Cellular Therapy, Teva Pharmaceuticals, Tigenix & Vericel Corporation